If you were watching TransCode Therapeutics (NASDAQ: RNAZ) on May 2, 2025, you probably saw what we saw – a stock on fire. RNAZ+3.57%
It opened quietly that morning around $0.42, but within hours, it had already doubled in volume, then doubled again. When we checked the tape mid-session, RNAZ was trading at $0.59, and volume had just passed 59 million shares. It was one of the most active microcap biotechs on the screen – and it had no fresh press release to back it up.
Naturally, we flagged it. Not because we were predicting a breakout or a crash, but because that kind of move almost always means something’s going on – whether it’s based on news, hype, or pure speculation.
Now that the dust has settled, let’s walk through what happened with RNAZ from May 1 through May 9. It’s a case that perfectly captures how biotech trades can heat up fast… and cool off even faster.
What Is TransCode Therapeutics?
Before we dive in, a quick refresher.
TransCode Therapeutics is a clinical-stage biotech working on RNA-targeted cancer treatments. Their lead candidate, TTX-MC138, is designed to target miR-10b, a genetic marker linked to metastatic cancers.
It’s the kind of pipeline that has long-term potential – but like many small-cap biotechs, most of the company’s value is tied to clinical trial milestones, and it doesn’t trade on revenue or earnings. Which means when momentum comes, it comes fast – and when it leaves, it often vanishes.
**Note: This image was generated using AI for illustrative purposes only. It does not depict an actual product, location, event, or individual.
May 2: The Day Everything Moved
Let’s go back to the moment of the alert.
It’s mid-morning. RNAZ is trading at $0.59, and it’s moving with force. Earlier that week, on May 1, the stock had closed at just $0.41, on under 100,000 shares of volume. But now? It’s flying.
We noted 59 million shares traded already – and by the end of the day, that number would hit 191.84 million. That’s not a typo.
But here’s the strange part: there was no news. No filings. No earnings call. No PR from the company. Just raw momentum and crowd energy. We’ve seen this before, and it usually means traders are buying the rumor – before the story is even written.
What Came Next: The News (And the Decline)
A few days later – on May 8 – TransCode finally made a public statement. They announced successful dosing in Cohort 4 of their Phase 1a clinical trial. And you know what? The results were good.
- 15 patients treated
- No major safety issues
- Signs of drug activity (target engagement)
- 10 patients still stable, with no disease progression
In biotech language, this is a green light to continue. The company even said it plans to move forward into Phase 1b – a crucial step in clinical development.
Also worth noting: TransCode had already announced a 1-for-28 reverse stock split, set to go live on May 15. That’s a move designed to lift the share price and keep RNAZ compliant with NASDAQ’s minimum bid rules.
So we got positive science. A compliance plan. A clear path forward.
And yet… the stock dropped.
From Momentum to Silence
After its $0.59 push on May 2, RNAZ never got back to that level. Instead, it faded.
Here’s how the trend looked:
- May 3–6: A slow slide. RNAZ closed at $0.42
- May 7–8: Even with the clinical trial news, the stock kept drifting down
- May 9: RNAZ traded at $0.3502 with daily volume around 550,000 shares
Think about that for a second. From nearly 200 million shares traded in a day, we dropped to half a million. That’s a 99.7% volume collapse.
So what happened?
The Bigger Picture: Trading the Setup, Not the Science
If you’ve followed small-cap biotech for a while, you know this story. Traders pile in before news – sometimes on real anticipation, sometimes on nothing at all. The stock rips, then the news comes out… and it’s solid, but not a game-changer.
Then? The price bleeds lower, and the crowd moves on.
That’s exactly what we saw with RNAZ. The trial results were good. But they were early-phase, not yet pivotal. They didn’t include full data or timelines. So after the initial excitement, there wasn’t enough to keep the price up.
And the reverse split? It’s useful for the listing – but not exactly a catalyst for upside. Many traders see splits like this as defensive moves, not growth signals.
What You Can Learn From RNAZ
Here are three takeaways you should keep in mind:
1. Don’t chase momentum without context.
Just because a stock is moving doesn’t mean there’s a reason. On May 2, RNAZ looked unstoppable – but it had no fuel behind the fire.
2. Wait for the full picture.
By May 8, we had the real news. It was good, but if you bought at $0.59 expecting a breakout, you likely saw red by week’s end.
3. Volume tells a story.
That massive volume spike on May 2? It vanished by May 9. Without sustained interest, even promising stocks can fade fast.
Final Thoughts
RNAZ gave us a perfect case study: a sharp, speculative move driven by pre-news enthusiasm, followed by a return to reality – even after legitimate clinical progress.
The science may continue. The trial may succeed. But the trade? That window closed almost as quickly as it opened.
If you’re navigating biotech volatility, don’t just ask “what’s the news?” – ask when it’s priced in, and what happens next.
And when you see something run without explanation? Take a beat. Ask the right questions. The real move might already be behind you.
Pump Radar
Stock Alerts